TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability
Brief Summary: This multi-center (6 sites: Helsinki, Kuopio, Oulu, Seinäjoki, Turku, Vantaa) intervention study aims to prevent cognitive impairment, dementia and disability in 60-77 year old persons at an increased dementia risk. The 2-year multi-domain life-style intervention includes nutritional guidance, exercise, cognitive training, increased social activity, and intensive monitoring and management of metabolic and vascular risk factors. The primary outcome is cognitive impairment measured by a sensitive Neuropsychological Test Battery (NTB), and Stroop and Trail Making tests to capture early cognitive impairment typical for both Alzheimer's disease and vascular dementia. We hypothesize that the multi-domain intervention will reduce cognitive impairment in the study group compared to the control group during the initial 2-year intervention period and reduce dementia incidence after the extended follow-up (until at least 300 participants have developed dementia).


Options:
A: Arm Label: Non-action video game training; Type: EXPERIMENTAL; Interventions: Other: Non-action video game training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Non-action video game training; Assigned to Arm(s): Non-action video game training
B: Arm Label: Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Lumosity Cognitive Training | Arm Label: Crossword Puzzles; Type: ACTIVE_COMPARATOR; Interventions: Other: Crossword Puzzles | Intervention Type: OTHER; Name: Lumosity Cognitive Training; Assigned to Arm(s): Cognitive Training | Intervention Type: OTHER; Name: Crossword Puzzles; Assigned to Arm(s): Crossword Puzzles
C: Arm Label: ThinkingFit; Type: EXPERIMENTAL; Interventions: Procedure: ThinkingFit programme | Intervention Type: PROCEDURE; Name: ThinkingFit programme; Assigned to Arm(s): ThinkingFit
D: Arm Label: Standard health counseling at baseline; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Nutritional guidance, Behavioral: Exercise, Behavioral: Cognitive training, Other: Reduction of vascular risk factors | Intervention Type: BEHAVIORAL; Name: Nutritional guidance; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: Reduction of vascular risk factors; Assigned to Arm(s): Lifestyle counseling

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability
Brief Summary: This multi-center (6 sites: Helsinki, Kuopio, Oulu, Seinäjoki, Turku, Vantaa) intervention study aims to prevent cognitive impairment, dementia and disability in 60-77 year old persons at an increased dementia risk. The 2-year multi-domain life-style intervention includes nutritional guidance, exercise, cognitive training, increased social activity, and intensive monitoring and management of metabolic and vascular risk factors. The primary outcome is cognitive impairment measured by a sensitive Neuropsychological Test Battery (NTB), and Stroop and Trail Making tests to capture early cognitive impairment typical for both Alzheimer's disease and vascular dementia. We hypothesize that the multi-domain intervention will reduce cognitive impairment in the study group compared to the control group during the initial 2-year intervention period and reduce dementia incidence after the extended follow-up (until at least 300 participants have developed dementia).


Options:
A: Arm Label: Exercise Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention | Arm Label: Exercise Control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise Control | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise Intervention Group | Intervention Type: BEHAVIORAL; Name: Exercise Control; Assigned to Arm(s): Exercise Control group
B: Arm Label: Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Lumosity Cognitive Training | Arm Label: Crossword Puzzles; Type: ACTIVE_COMPARATOR; Interventions: Other: Crossword Puzzles | Intervention Type: OTHER; Name: Lumosity Cognitive Training; Assigned to Arm(s): Cognitive Training | Intervention Type: OTHER; Name: Crossword Puzzles; Assigned to Arm(s): Crossword Puzzles
C: Intervention Type: PROCEDURE; Name: Computer-based training for Mild Cognitive Impairment (MCI); Assigned to Arm(s): N/A
D: Arm Label: Standard health counseling at baseline; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Nutritional guidance, Behavioral: Exercise, Behavioral: Cognitive training, Other: Reduction of vascular risk factors | Intervention Type: BEHAVIORAL; Name: Nutritional guidance; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: Reduction of vascular risk factors; Assigned to Arm(s): Lifestyle counseling

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability
Brief Summary: This multi-center (6 sites: Helsinki, Kuopio, Oulu, Seinäjoki, Turku, Vantaa) intervention study aims to prevent cognitive impairment, dementia and disability in 60-77 year old persons at an increased dementia risk. The 2-year multi-domain life-style intervention includes nutritional guidance, exercise, cognitive training, increased social activity, and intensive monitoring and management of metabolic and vascular risk factors. The primary outcome is cognitive impairment measured by a sensitive Neuropsychological Test Battery (NTB), and Stroop and Trail Making tests to capture early cognitive impairment typical for both Alzheimer's disease and vascular dementia. We hypothesize that the multi-domain intervention will reduce cognitive impairment in the study group compared to the control group during the initial 2-year intervention period and reduce dementia incidence after the extended follow-up (until at least 300 participants have developed dementia).


Options:
A: Arm Label: Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Lumosity Cognitive Training | Arm Label: Crossword Puzzles; Type: ACTIVE_COMPARATOR; Interventions: Other: Crossword Puzzles | Intervention Type: OTHER; Name: Lumosity Cognitive Training; Assigned to Arm(s): Cognitive Training | Intervention Type: OTHER; Name: Crossword Puzzles; Assigned to Arm(s): Crossword Puzzles
B: Arm Label: cognitive training; Type: EXPERIMENTAL; Interventions: Device: CogniFit Personal Coach® | Intervention Type: DEVICE; Name: CogniFit Personal Coach®; Assigned to Arm(s): cognitive training
C: Arm Label: Standard health counseling at baseline; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Nutritional guidance, Behavioral: Exercise, Behavioral: Cognitive training, Other: Reduction of vascular risk factors | Intervention Type: BEHAVIORAL; Name: Nutritional guidance; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: Reduction of vascular risk factors; Assigned to Arm(s): Lifestyle counseling
D: Arm Label: Exercise Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention | Arm Label: Exercise Control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise Control | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise Intervention Group | Intervention Type: BEHAVIORAL; Name: Exercise Control; Assigned to Arm(s): Exercise Control group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Energy Dense Oleic Acid Rich Formula to Newly Admitted Geriatric Patients - Feasibility and Effects on Energy Intake
Brief Summary: Background and aims:

Old patients seldom reach energy requirements. The effects of an oleic-acid rich formula on energy intake and appetite were studied.

Methods: Recently admitted geriatric patients (n=71), likely to stay more than 1 week were randomised to receive a fat emulsion (Calogen, intervention group (IG)) or to standard care (control group (CG)). Thirty ml of the emulsion were given 3 times daily, i.e. 420 kcal, and was distributed at the regular medication rounds. Food intake and self-rated appetite were registered 2-3 days after admission and on day 8 or the day prior to discharge. Nutritional risk screening (NRS) 2002 and serum lipids and fatty acid profiles were analysed.


Options:
A: Arm Label: Dietary Advice; Type: OTHER; Interventions: Behavioral: Dietary Advice | Arm Label: Oral Nutritional Supplements; Type: OTHER; Interventions: Dietary Supplement: Oral Nutritional Supplements (Fortisip) | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Dietary Advice | Intervention Type: DIETARY_SUPPLEMENT; Name: Oral Nutritional Supplements (Fortisip); Assigned to Arm(s): Oral Nutritional Supplements
B: Arm Label: Intervention with energy dense formula; Type: EXPERIMENTAL; Interventions: Other: Calogen® - an energy dense oleic acid based formula | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Calogen® - an energy dense oleic acid based formula; Assigned to Arm(s): Intervention with energy dense formula
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: "brain preservation' diet | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: "brain preservation' diet; Assigned to Arm(s): 1
D: Arm Label: usual mealtime care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: mealtime assistance; Type: EXPERIMENTAL; Interventions: Other: trained volunteer mealtime assistance | Intervention Type: OTHER; Name: trained volunteer mealtime assistance; Assigned to Arm(s): mealtime assistance

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients
Brief Summary: This prospective multicenter, double blind study will evaluate the efficacy and safety of aliskiren versus ramipril in patients with moderate systolic essential hypertension.


Options:
A: Arm Label: Ramipril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Drug: Matching placebo to Aliskiren | Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Matching placebo to Ramipril | Arm Label: Placebo to Ramipril; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo to Ramipril | Arm Label: Placebo to Aliskiren; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo to Aliskiren | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril | Intervention Type: DRUG; Name: Matching placebo to Aliskiren; Assigned to Arm(s): Placebo to Aliskiren, Ramipril | Intervention Type: DRUG; Name: Matching placebo to Ramipril; Assigned to Arm(s): Aliskiren, Placebo to Ramipril
B: Arm Label: Aliskiren-based regimen; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Hydrochlorothiazide, Drug: Amlodipine | Arm Label: Ramipril-based regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Drug: Hydrochlorothiazide, Drug: Amlodipine | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren-based regimen | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril-based regimen | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Aliskiren-based regimen, Ramipril-based regimen | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Aliskiren-based regimen, Ramipril-based regimen
C: Arm Label: Combination Aliskiren / Enalapril; Type: EXPERIMENTAL; Interventions: Drug: Enalapril, Drug: Aliskiren | Arm Label: Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren | Arm Label: Enalapril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enalapril | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): Combination Aliskiren / Enalapril, Enalapril | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren, Combination Aliskiren / Enalapril
D: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Status and Dose Response in Infants
Brief Summary: This study will examine the relationship of serum 25(OH)D levels in infants 32 weeks and greater gestation who are fed infant formula to markers of inflammation and bone metabolism.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 3
C: Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Placebo, Vitamin D
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: vitamin D3 placebo | Arm Label: Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D3 placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Safety and Efficacy Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Coronary Heart Disease (CHD) Patients With a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus (T2D)
Brief Summary: This double-blind, parallel, two-arm study will evaluate the potential to reduce cardiovascular risk, the tolerability and long-term safety profile of aleglitazar compared to placebo on top of standard care in patients with recent acute coronary syndrome (ACS) and type 2 diabetes mellitus. Patients will be randomized to receive either aleglitazar or placebo once daily as oral doses. The study will last until at least 950 events occur, but time on study treatment will be for at least 2.5 years.


Options:
A: Arm Label: Pioglitazone QD; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD
B: Arm Label: Aleglitazar; Type: EXPERIMENTAL; Interventions: Drug: Aleglitazar | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aleglitazar; Assigned to Arm(s): Aleglitazar | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: rosiglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: rosiglitazone | Arm Label: TZD placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Arm Label: Vitamin D placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): pioglitazone | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): rosiglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): TZD placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Vitamin D placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Partnerships to Overcome Obesity Disparities in Hawaii
Brief Summary: The PILI 'Ohana CBPR partnership implemented a pilot study to determine whether a Family plus Community focused intervention will improve weight loss maintenance compared to Standard follow-up in overweight/obese Native Hawaiian (NH) and other Pacific People (PP) adults (\> 18 yr. old) after receiving a standard individual-focused behavioral intervention. The primary hypothesis was that overweight/obese NH and PP adults that undergo a combined family-focused plus community-focused intervention vs. a standard follow-up after receiving a standard individual-focused behavioral intervention will have significantly higher rates of weight loss maintenance.


Options:
A: Arm Label: Family plus community focused intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PILI 'Ohana Lifestyle Program | Arm Label: Standard Behavioral Weight Loss Maintenance Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Behavioral Weight Loss Maintenance Program | Intervention Type: BEHAVIORAL; Name: PILI 'Ohana Lifestyle Program; Assigned to Arm(s): Family plus community focused intervention | Intervention Type: BEHAVIORAL; Name: Standard Behavioral Weight Loss Maintenance Program; Assigned to Arm(s): Standard Behavioral Weight Loss Maintenance Intervention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Breaking Down Barriers | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Breaking Down Barriers | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Breaking Down Barriers | Intervention Type: BEHAVIORAL; Name: Breaking Down Barriers; Assigned to Arm(s): 1, 2, 3
C: Arm Label: Diabetes-Specific CBT (DS-CBT); Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes-Specific CBT (DS-CBT) | Arm Label: Standard Diabetes Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Diabetes Education | Intervention Type: BEHAVIORAL; Name: Diabetes-Specific CBT (DS-CBT); Assigned to Arm(s): Diabetes-Specific CBT (DS-CBT) | Intervention Type: BEHAVIORAL; Name: Standard Diabetes Education; Assigned to Arm(s): Standard Diabetes Education
D: Arm Label: LIVE Arm; Type: EXPERIMENTAL; Interventions: Behavioral: LIVE | Arm Label: Website; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Website | Intervention Type: BEHAVIORAL; Name: LIVE; Assigned to Arm(s): LIVE Arm | Intervention Type: BEHAVIORAL; Name: Website; Assigned to Arm(s): Website

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®
Brief Summary: This multi-center, randomized, double-blind, active controlled, parallel-group study in type 2 diabetes patients with moderate renal impairment will evaluate the effect on renal function and the safety and tolerability of aleglitazar compared with pioglitazone. Patients will be randomized to receive either 150 mcg aleglitazar or 45 mg pioglitazone as daily oral doses. In addition, a diet and exercise plan will also be implemented during the anticipated time on study treatment of 52 weeks. The target sample size is 200-400 patients.


Options:
A: Arm Label: aleglitazar; Type: EXPERIMENTAL; Interventions: Drug: aleglitazar | Arm Label: pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Intervention Type: DRUG; Name: aleglitazar; Assigned to Arm(s): aleglitazar | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): pioglitazone
B: Arm Label: Linagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Arm Label: 1Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: CIIIT | Intervention Type: DRUG; Name: CIIIT; Assigned to Arm(s): Treatment

Answer: A